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92 Poster Session Irelevant inhibitory KIRs (KIR2DL1, KIR2DL2/KIR2DL3,
KIR3DL1). Conversely, examination of three established osteosar-
coma cell lines (HOS, SaOS, and U2OS) demonstrated significant
variability in cell surface KIR ligand expression (HLA-C groups 1
and 2, HLA-Bw4) by flow cytometry and qRTPCR. Following
a 12-hour incubation of donor NK cells with IL-2, lysis of osteosar-
coma targets was measured in an annexin V flow cytometric assay.
Greater KIR receptor-ligand incompatibility was predictive of
higher killing of osteosarcoma cells. These findings were consistent
using NK effectors from different donors. Additionally, we ob-
served that at high passage number (.20), SaOS cells demonstrated
down-regulation of KIR ligand expression. These changes corre-
lated with increased lysis by the same donor NK cells. Our findings
suggest: 1) Variable expression of KIR ligands in osteosarcoma al-
lows potential susceptibility to KIR-incompatible, NK cell-medi-
ated lysis; 2) The killing of osteosarcoma cells by NK cells can be
predicted by the degree of receptor/ligandmismatch; and 3) During
expansion, osteosarcoma cells may down-regulate expression of
KIR ligands, resulting in increased susceptibility to lysis by KIR-in-
compatible NK cells. Further studies are needed to explore the util-
ity of KIR-incompatible, haploidentical stem cell transplantation
for patients with recurrent or metastatic osteosarcoma.249
PROLONGED SURVIVAL FOR ULTRA HIGH-RISK PEDIATRIC SARCOMA
PATIENTS FOLLOWING REDUCED-INTENSITY ALLOGENEIC STEM CELL
TRANSPLANTATION (ALLOSCT)
Baird, K.1, Love, C.1, Steinberg, S.M.3, Mackall, C.L.1, Wayne, A.S.1,
Fry, T.J.2. 1National Cancer Institute, NIH, Bethesda, MD; 2Children’s
National Medical Center, Washington, DC; 3National Cancer Institute,
NIH, Bethesda, MD.
Background: Pediatric sarcomas with ultra high-risk features
have overall survival rates of\20% and autologous transplantation
has not substantially improved outcome. AlloSCT can cure pediat-
ric hematologic malignancies, in part due to a graft versus tumor
(GVT) effect. The use ofmyeloablative alloSCT in sarcoma has his-
torically been limited by excessive toxicity.We piloted a reduced in-
tensity alloSCT (RISCT) regimen in pediatric sarcoma patients.
Methods: 18 patients with ultra-high risk features (Table) were
transplanted. Induction chemotherapy was administered for disease
control and targeted CD4 count reduction. Pre-transplant condi-
tioning consisted of cyclophosphamide 1,200 mg/m2/day  4, flu-
darabine 30 mg/m2/day  4 and melphalan 100 mg/m2  1.
Grafts were G-CSF mobilized unmodified peripheral blood stem
cells from 5–6/6 HLA-matched siblings. An initial cohort (n 5
13) received cyclosporine for GVHD prophylaxis and a second (n
5 5) received tacrolimus and sirolimus. Results: The regimen
was well tolerated with no transplant related mortality. All patients
had rapid engraftment and achieved full donor chimerism by post-
SCT day (D1) 28. Immune recovery was surprisingly brisk (median
CD41 count 309/mm3 D 1 28–42). 15/18 recipients developed
aGVHD: 13 grade 1–2 and 2 grade 3. 13/13 patients surviving .
100 days receiving cyclosporine as a single agent for GVHD pro-
phylaxis developed cGVHD whereas only 2/5 in the tacrolimus/si-
rolimus cohort have developed cGHVD. Median survival from
initial diagnosis is 35 months and from SCT is 13.9 months. Cur-
rently 6 patients are alive, 2 with no evidence of disease. Despite
early relapses, many patients experienced prolonged survival and
apparent improved responsiveness to chemotherapy, suggesting
a change in the natural history of these aggressive tumors following
alloSCT. Conclusions: Ultra high-risk sarcoma patients tolerated
RISCTwell and experienced brisk engraftment with kinetics similar
to myeloablative regimens. Alteration of GVHD prophylaxis ap-
pears to have decreased GVHD rates and severity. Median survival
compares favorably with outcomes in similarly ultra high-risk pa-
tients who did not undergo SCT. Given the rapid immune recovery
and favorable survival, this regimen appears to be a promising plat-
form for post-transplant immune-based therapy in pediatric sar-
coma patients.Patient Features
Number ofAge (yrs) DiagnosisUltra
high-risk
featuresprior
treatment
regimensDisease
status at
on-study/SCTDay 28–42
CD4
count/mm3Time to
relapse/PD
(days)Survival
post-SCT
(mos)20 RMS MR 5 PD/PR 253 100 34.019 RMS MR 3 PD/SD 442 42 4.310 EWS ER, MR 2 PD/SD 324 28 3.614 EWS ER, B/BM 3 PD/SD 335 100 5.818 RMS B/BM 2 PD/SD 443 100 14.521 EWS PD, B/BM 1 PD/SD 226 160 20.718 RMS MR 2 PD/SD 176 60 7.329 EWS B/BM 2 PD/SD 294 100 24.812 RMS MR 3 NED/NED 205 100 35.2*15 RMS B/BM 2 PD/SD 241 70 13.38 EWS B/BM 1 NED/NED 152 NED 8.9£19 EWS PD 1 PD/PD 481 42 32.2*25 EWS B/BM 2 PD/PD 148 100 14.925 DSRCT Metastatis§ 2 NED/NED 903 150 28.6*18 EWS B/BM 3 PD/PD 1003 38 4.415 EWS B/BM 1 NED/NED 171 NED 19.0*,£21 EWS B/BM 1 PD/PR 346 100 11.5*14 DSRCT Metastatic§ 2 NED/NED 463 NED 7.6*,£Median 17.8 Median 309 Median 13.9Key: RMS - rhabdomyosarcoma; EWS - Ewing sarcoma; DSRCT -
desmoplastic small round cell tumor; MR - multiply recurrent;
ER - early relapse within 1 year of diagnosis; B/BM - bone or
bone marrow metastasis at diagnosis; PD - progressive disease;
SD - stable disease; PR - partial response; NED - no evidence
of disease; mos - months; yrs - years
§Any metastatic site at diagnosis for DSRCT.
*Alive.
£No evidence of disease.250
LONG-TERM CLINICAL OUTCOME OF HIGH DOSE CHEMOTHERAPY
WITH AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION
(HDCT/ASCT) FOR BREAST CANCER PATIENTS
Jeong, S.H., Lee, H.W., Kang, S.Y., Park, J.S., Choi, J.H., Kim, H.C.
Ajou University School of Medicine, Suwon, Kyeong-Ki Do, Korea.
Background: Previous studies have shown that HDCT/ASCT
offer no survival advantage to standard treatment modality for
breast cancer in a short follow-up group. We have followed breast
cancer patients with HDCT/ASCT in a long-term follow up (me-
dian follow up 114.5months, ranges 79–142).Method:Forty-seven
consecutive patients who received HDCT/ASCT for treating
breast cancer at Ajou University Hospital between Dec. 1995 and
Mar. 2001 were reviewed retrospectively. Overall survival (OS),
progression free survival (PFS) and other clinical data were calcu-
lated according to the disease status at transplant. Student’s t-test
was done for statistics.Result:Themedian age was 43 years (ranges
27–59). Out of 47 patients, 11 were high risk for relapse, 9 were sen-
sitive relapse, 22 were refractory relapse and 5 were primary meta-
static disease before transplant. In high risk group, 6 patients were
stage IIIA, 5 were II with intensive lymph node infiltrations. Pa-
tients with primary metastatic cancer or refractory relapse showed
poor outcome (20% and 4.6% at 100 months, respectively). High
risk group maintained survival of 63.6% after 120 months whereas
sensitive relapse group showed 33.3% at 80 months. In high risk
group, TNM stage did not affect onOS or PFS, but ER/PR positive
group showed survival advantage over double negative group (p 5
0.0019), whereas C-erbB2 status did not affect the survival. Con-
clusion: Long-term follow up of clinical data suggests that
HDCT/ASCToffers as an alternative treatmentmodality for breast
cancer especially in case of high risk for relapse group with ER/PR
positive. Key Words: Breast Cancer, Myeloablative therapy, He-
matopoietic Stem Cell Transplantation.
